MedElevator Войти в исследования
← Поиск публикаций

DOI 10.14309/ajg.0000000000003771

Медицинская библиотека · The American journal of gastroenterology · 2025

Role of Prucalopride in the Treatment of Chronic Constipation in Parkinson Disease: A Randomized Controlled Trial.

Preechakawin Nutchanun, Maneerattanaporn Monthira, Geeratragool Tanawat, Srivanitchapoom Prachaya, Pitakpatapee Yuvadee, Leelakusolvong Somchai

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Constipation, a prevalent nonmotor symptom in Parkinson disease (PD), adversely affects patients' quality of life. Prucalopride, a selective serotonin type 4 receptor agonist, has shown efficacy as a treatment of functional constipation, but its role in PD-related constipation remains underexplored. The objective of this study was to assess the efficacy, safety, and quality-of-life impact of prucalopride in PD patients with chronic constipation.

METHODS

In this double-blind randomized controlled trial, PD patients with chronic constipation received prucalopride (2 mg) or placebo once daily for 8 weeks. The primary outcome was the change in the number of spontaneous bowel movements (SBMs) per week from baseline to week 8. Secondary outcomes included stool consistency, straining, and changes in Patient Assessment of Constipation-Symptoms and Patient Assessment of Constipation-Quality of Life scores. Parkinsonian motor severity was assessed using the Unified Parkinson Disease Rating Scale.

RESULTS

Fifty-seven patients were included (prucalopride = 30, placebo = 27). At week 8, the change in the number of weekly SBMs was significantly larger in the prucalopride group (3.2 ± 2.8) than in the placebo group (1.6 ± 1.9; P = 0.02). Longitudinal analysis confirmed a significantly higher SBM frequency in the prucalopride group throughout the 8-week period ( P = 0.015). Secondary outcomes showed trends toward improvement but no statistically significant differences. No serious adverse events were reported, and Unified Parkinson Disease Rating Scale scores remained unchanged.

DISCUSSION: Prucalopride was safe, well-tolerated, and more effective than placebo in increasing bowel movement frequency in PD patients with chronic constipation, supporting its potential as a therapeutic option in this population.

Для цитирования: Preechakawin Nutchanun, Maneerattanaporn Monthira, Geeratragool Tanawat, Srivanitchapoom Prachaya, Pitakpatapee Yuvadee, Leelakusolvong Somchai. Role of Prucalopride in the Treatment of Chronic Constipation in Parkinson Disease: A Randomized Controlled Trial.. The American journal of gastroenterology. 2025. DOI: 10.14309/ajg.0000000000003771.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.